SynAPPse: A Novel QSAR Modeling App for the Rapid Identification of AChE Inhibitors for Alzheimer's Disease
ISEF · 2024 Computational Biology and Bioinformatics
Overview
Alzheimer's Disease (AD) is a leading cause of death, affecting over 55 million worldwide. Despite its prevalence, there is no effective treatment or cure for AD. The acetylcholinesterase (AChE) protein is a promising target for AD treatment because inhibiting AChE can boost acetylcholine levels, crucial for cognition. However, existing AChE inhibitors, like donepezil, have success rates as low as 40%. Moreover, the speed and cost of standard screening techniques impede the search for novel inhibitors. Thus, this study aimed to develop a machine learning-based Quantitative Structure-Activity Relationship (QSAR) model to rapidly identify novel AChE inhibitors based only on their structural characteristics. First, an exploratory analysis of 119 molecules from the ChEMBL database compared Lipinski descriptor levels between biologically active and inactive molecules for AChE. U-tests revealed that molecular weight, number of hydrogen bond donors, and number of hydrogen bond acceptors levels were significantly lower in active molecules, while hydrophobicity levels were similar across active and inactive molecules. Next, 38 models were trained to predict AChE bioactivity using data containing 4695 molecules' structures. The decision tree model was shown to have the best accuracy (R-squared = 0.86), uniformity (RMSE = 0.57), and efficiency (0.16 seconds/molecule). The decision tree then screened 100,000 orally bioavailable molecules from ChEMBL with unknown bioactivities against AChE, yielding 221 novel molecule candidates. Given its speed and accuracy in identifying molecule candidates, this innovative machine learning-based QSAR modeling approach can advance therapeutic development for Alzheimer's Disease and also a broad spectrum of other diseases.
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2023
Machine Learning Identification of Potential PARP-1 Inhibitors for Alzheimer's Disease Treatment
ISEF · 2024
Novel Drug Discovery Methodology Using Machine Learning for Gene Expression-Based Virtual Screening Predicts Novel Compounds To Reverse Alzheimer's Disease With Applications to Cancer and Longevity by Inhibiting CtBP2 Expression
ISEF · 2022
Computational and Experimental Design of a Novel Acetylcholinesterase Inhibitor: Silanediols for Alzheimer's Disease Treatment
ISEF · 2026
AI-Driven Graph Neural Networks for Dual-Target AChE and BACE1 Drug Repurposing in Alzheimer’s Disease
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair